文献速递神经康复骨科与运动康复

重复注射A型肉毒毒素改善下肢痉挛的目标达成:前瞻性观察研究

Longitudinal Goal Attainment With Repeat Injections of AbobotulinumtoxinA in Adults With Lower Limb Spasticity: Results From a Prospective Observational Study.
PubMed 文献 · Arch Phys Med Rehabil · 2024-11-20

这项前瞻性国际多中心观察研究纳入384例可行走的下肢痉挛成人,评估重复注射abobotulinumtoxinA(AboBoNT-A)16个月内的目标达成情况。结果显示累积GAS-leg T评分从基线38.0升至16个月时48.2,平均变化9.9;基线使用注射引导技术者首次治疗周期目标达成几率更高(OR 1.9)。

要点

  • 重复AboBoNT-A注射16个月可改善下肢痉挛患者的目标达成。
  • 基线使用注射引导技术者首次周期目标达成几率更高(OR 1.9)。
  • 治疗相关不良事件发生率低(1.4%)。

核心结论

  • 重复AboBoNT-A治疗周期对下肢痉挛患者具有获益证据,且首次周期目标达成与注射引导技术相关。

研究设计与样本

  • 前瞻性、纵向、国际、多中心观察性研究(NCT04050527),纳入384例可行走的下肢痉挛成人。

主要发现

  • 患者中位接受5个下肢注射周期,中位剂量600U(范围100-1475U),平均注射间隔18.3±6.1周。
  • 第1周期基线GAS-leg T评分均值38.0(95%CI 37.7, 38.3),16个月累积GAS-leg T评分均值48.2(95%CI 47.4, 48.9),平均变化9.9(95%CI 9.1, 10.7)。
  • 56例(13.5%)报告至少1次不良事件,其中6例(1.4%)为治疗相关不良事件。

关键数值与推荐

  • 目标达成采用累积GAS-leg T评分评估,覆盖每位患者所有治疗周期。

临床怎么用

  • 对下肢痉挛成人可考虑重复AboBoNT-A注射以促进个体化治疗目标达成。
  • 注射时使用引导技术可能提高首次治疗周期的目标达成几率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess longitudinal goal attainment with repeat abobotulinumtoxinA (AboBoNT-A) injections for lower limb spasticity (LLS) over 16 months. DESIGN: Prospective, longitudinal, international, multicenter, observational study (NCT04050527). SETTING: Specialist neurorehabilitation centers. PARTICIPANTS: Ambulatory adults with unilateral LLS able to take ≥5 steps with/without assistance (effectiveness population, N=384). INTERVENTIONS: Participants received ≥1 AboBoNT-A treatment cycle administered in accordance with local prescribing guidelines to achieve individualized treatment goals. MAIN OUTCOME MEASURES: The primary endpoint was goal attainment as assessed using the cumulated Goal Attainment Scaling-Leg (GAS-leg) T score, across all treatment cycles for each patient. RESULTS: Overall, participants underwent a median of 5 lower limb injection cycles (median dose 600U, range 100-1475U) with a mean±SD injection interval of 18.3±6.1 weeks. Participants generally achieved their goals as expected over repeated cycles; the mean (95% CI) GAS-leg T score at cycle 1 baseline was 38.0 (37.7, 38.3) and the mean cumulated GAS-leg T score at 16 months was 48.2 (47.4, 48.9) (mean change from a baseline of 9.9 [9.1, 10.7]). Participants injected with a guidance technique at baseline were more likely to attain their cycle 1 primary treatment goals (odds ratio: 1.9 [95% CI 1.1, 3.1], P=.02). Overall, 56 (13.5%) participants reported ≥1 adverse event, of which 6 participants (1.4%) had a treatment-related adverse event. CONCLUSIONS: Findings from this large, international study provide evidence for the benefit of repeated cycles of AboBoNT-A for LLS. Multivariate analyses indicated that goal attainment during the first cycle was better with those injected using injection guidance than those injected without guidance.

来源:Arch Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Esquenazi A, Zorowitz RD, Ashford S, et al. Longitudinal Goal Attainment With Repeat Injections of AbobotulinumtoxinA in Adults With Lower Limb Spasticity: Results From a Prospective Observational Study. Arch Phys Med Rehabil. 2024. PMID: 39571744. doi:10.1016/j.apmr.2024.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。